Antibodies with only one (instead of two) protein chain derived from only one of the domains of the antibody structure. Dabs exploit the finding that, for some antibodies, half of the antibody molecule binds to its target antigen almost as well as the whole molecule. The potential advantages of dabs are that they can be made easily by bacteria or yeasts, and offer a way to clone antibody-like molecules into bacteria, and hence to be able to easily screen millions of antibodies. Related ideas are single-chain antigen binding technology (SCA), biosynthetic antibody binding sites (BABS), minimum recognition units (MRUs), and complementary determining regions (CDRs).